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Hyoung Jin Kang,1 Hee Young Shin,1 Jun Eun Park,2 Nak Gyun Chung,3 Bin Cho,3
Hack Ki Kim,3 Sun Young Kim,4 Young Ho Lee,5 Young Tak Lim,6
Keon Hee Yoo,7 Ki Woong Sung,7 Hong Hoe Koo,7
Ho Joon Im,8 Jong Jin Seo,8 Sang Kyu Park,9 Hyo Seop Ahn1, on behalf of The Korean
Society of Pediatric Hematology-OncologyAntithymocyte globulin (ATG) has been used in severe aplastic anemia (SAA) as part of the conditioning reg-
imen. Among the many kinds of ATG preparations, thymoglobulin had been found to be more effective for
preventing graft-versus-host disease (GVHD) and the rejection of organ transplants. After the promising
results of our preliminary study, we conducted a phase II prospective multicenter clinical trial using a fludar-
abine (Flu), cyclophosphamide (Cy), and thymoglobulin conditioning regimen to allow good engraftment in
patients who underwent unrelated transplantation for SAA. Twenty-eight patients underwent bone marrow
(N5 15) or mobilized peripheral blood (N5 13) transplantation fromHLA-matched unrelated donors with
Cy (50mg/kg once daily intravenously (i.v.) on days29,28,27, and26), Flu (30mg/m2 once daily i.v. on days
25,24,23, and22), and thymoglobulin (2.5 mg/kg once daily i.v. on days23,22, and21). Donor-type he-
matologic recovery was achieved in all patients. The estimated survival rate (SR) was 67.9%, and all the events
were treatment-related mortality (TRM), which included thrombotic microangiopathy (N 5 2), pneumonia
(N5 1), myocardiac infarction (N5 1), posttransplantation lymphoprolifarative disease (N5 3), and chronic
GVHD-associated complications (N 5 2). The SR of patients who received bone marrow (60.0%) was not
different from that of patients who received mobilized peripheral blood (76.9%) (P 5 .351), but the SR of
patients who received more than 15 units of red blood cells before transplantation (45.5%) was significantly
lower than that of the other patients (82.4%) (P5.048). The Flu, Cy, and thymoglobulin conditioning regimen
achieved promising results for successful engraftment, but the TRM was high. This study was registered
at www.clinicaltrials.gov (NCT00737685), and now we are performing a new multicenter study
(NCT00882323) to decrease the TRM by reducing the dose of Cy.
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Hematopoietic stem cell transplantation (HSCT)
with a matched related donor is a curative therapy for
severe aplastic anemia (SAA), and cyclophosphamide
(Cy)-based conditioningwith orwithout antithymocyte
globulin (ATG) is known to be optimal for HSCTwith
a matched related donor [1,2]. However, many patients
have no appropriate related donor, and they need
another treatment such as immunosuppressive therapy
(IST) and/or stem cell transplantation (SCT) with an
alternative donor. Transplantation with a matched
unrelated donor (MUD) is associated with a high
incidence of rejection, and the conditioning regimen
for related donor transplantation is insufficient for
HSCT with an MUD [3]. Two kinds of strategies
have been developed to improve the engraftment by in-
creasing the immunosuppressive activity of the condi-
tioning regimen, but only 2 multicenter prospective
studies have been conducted on this. One multicenter
study in United State was conducted with adding total
body irradiation (TBI) to Cy and ATG [4,5], and
another was done by the European Group for Blood
and Marrow Transplantation Severe Aplastic Anemia
Working Party (EBMT-SAAWP) using the
combination of fludarabine (Flu), Cy, and ATG [6].
These 2 studies included ATG, which has been
commonly used for SAA as a part of the conditioning
regimens.Among themany kinds ofATG, thymoglobu-
lin (a rabbit-derived antithymocyte polyclonal antibody)
is known to be more potent than the other available
preparations, and it has been found to be more effective
for preventing GVHD and the rejection of organ
transplants [7-9]. Previously, we have reported the
promising preliminary results of a Flu, Cy, and
thymoglobulin conditioning regimen in matched
unrelated transplantation for SAA [10]. After the prom-
ising results of our pilot study, the phase II prospective
multicenter clinical trial was first conducted in Asia
withaFlu,Cy, and thymoglobulin conditioning regimen
to achieve good engraftment in unrelated transplanta-
tion for SAA.PATIENTS AND METHODS
Patient and Donor Selection
FromFebruary 2006 toMay 2008, 28 patients with
SAA received HSCT from HLA matched unrelated
donors at multicenter in Korea. Those patients, with
the diagnosis of SAA, patients without prior HSCT,
patients who had ECOG 0-2 performance status,
patients who were free of significant functional deficits
in major organs, and patients without any active viral
infections or active fungal infection, were included in
this study. Pregnant or nursing woman, patients with
a malignant or nonmalignant illness that was uncon-trolled or whose control had been jeopardized by com-
plications of study therapy, patients with a psychiatric
disorder that would preclude compliance, and patients
with congenital AA including Fanconi anemia, were
excluded. Transplantation performed at median 13
(3-210) months after the diagnosis of SAA. The clinical
characteristics of patients are summarized in Table 1.
The selection of donors was based on HLA serologic
typing performed for class I antigens and HLA
molecular typing for the DRB1 loci. HLA-A, -B, -C,
and -DRB1 were confirmed by a high-resolution
molecular method for all patients and donors. All
patients received the designed conditioning regimen
after obtaining informed consents from them or their
guardians. This studywas approved by the institutional
review board of each center and registered at www.
clinicaltrials.gov (NCT00737685).
Conditioning Regimen
The conditioning regimen was the same as that of
the previous pilot study; the regimen was composed of
Cy (50 mg/kg once daily intravenously [i.v.] on days
29, 28, 27, and 26), Flu (30 mg/m2 once daily i.v.
on days 25, 24, 23, and 22), and thymoglobulin
(SangStat, Lyon, France and Genzyme, Cambridge,
MA) (2.5 mg/kg once daily i.v. on days 23, 22, and
21) [10]. Patients received adequate hydration during
the conditioning chemotherapy, and they also received
mesna to prevent hemorrhagic cystitis. Unmanipu-
lated bone marrow (BM) or mobilized peripheral
blood (PB) harvest was infused on day 0 of the
conditioning regimen.
Graft-versus-Host Disease (GVHD) Prophylaxis
and Supportive Care
Weallowed the use of each institution’s protocol for
GVHD prophylaxis. Patients received combination of
cyclosporine (CsA) or tacrolimus (FK), and methotrex-
ate (MTX), with or without posttransplant low-dose
thymoglobulin (pATG: 1.25 mg/kg once daily i.v. on
days 7, 9, and 11) (Table 2) [11,12]. Supportive care
was done according to the guidelines for each
institution.
Assess Engraftment and Toxicities
Myelogenous engraftment was defined as the first
of 3 consecutive days with an absolute netrophil count
(ANC) of 0.5  109/L, and platelet recovery was
defined as the day the platelet count was 20  109/L
without platelet transfusions. The BM was examined
for morphology and cellularity at 1, 3, and 6 months,
and 1 year after transplantation.Hematopoietic chime-
rism was evaluated by molecular analysis. Secondary
graft failure was defined as engraftment followed by se-
vere neutropenia (ANC\0.5  109/L) or the absence
of donor cells in the BM or blood as demonstrated by
Table 1. Clinical Characteristics of Enrolled Patients
Median age, Years (range) 13.5 (1-30)
Sex, No. (%)
Male 17 (60.7)
Female 11 (39.3)
Interval from diagnosis to transplantation, No. (%)
<1 year 13 (46.4)
$1 year 15 (53.7)
History of pervious IST, No. (%)
Yes 14 (50.0)
No 14 (50.0)
History of RBC transfusion, No. (%)
<15 units 17 (60.7)
$15 units 11 (39.3)
IST indicates immune suppressive therapy (with regimens including
antithymocyte globulin); RBC, red blood cells.
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occurring either spontaneously or after treatment
with growth factor. BM or PB stem cell (PBSC) reinfu-
sion, which was carried out at any time after day 0 be-
cause of inadequate hematopoietic function, was
taken as a definitive indicationof graft failure regardless
of ANC values and BM cellularity. The regimen-
related toxicity until 42 days after transplantation was
graded according to theNCICommonToxicityCrite-
ria for BM transplant (BMT) recipients (CTC 2.0).
Statistics
This trialwasdesigned todetect improvementof the
engraftment rate and a 2-stage optimal design proposed
by Simon was used for this trial (P 5 .05, power 80%).
Theengraftment rate in treatmentgroupswas estimated
by the proportion of the responders and the target
engraftment rate was 95% (a 15% increases over theTable 2. Transplantation Data of Patients Received Bone Marrow (
Stem cell sources
Infused cells dose, (range)
TNC, 107/kg
CD34, 105/kg
HLA disparity, 8/8 (HLA-A, B, C and DR by high-resolution molecular method)
0/8
1/8
3/8
GVHD prophylaxis
CsA + MTX + pATG*
CsA + MTX
FK + MTX
Engraftment, median days (range)
ANC of more than 0.5  109/L
Regimen related toxicities†
Grade III-IV
Acute GVHD
Grade II
Grade III
Grade IV
Chronic GVHD/patients survived 100 days
Limited
Extensive
CsA indicates cyclosporine; CMV, cytomegalovirus; FK, FK506/tacrolimus; GVH
tation lymphoproliferative disease; TNC, total nucleated cell.
*pATG: posttransplantation low-dose thymoglobulin (1.25 mg/kg once daily i.v
†Toxicities assessed 42 days after transplantation.
‡Estimated by cumulative incidence.historic rate of 80%) [13]. If 7 or fewer engraftments
were observed among 9 patients in first stage, accrual
would stop with the conclusion that the regimen did
not hold promise for further study. Otherwise, accrual
continued to a total of more than 29 patients. At the
end of second stage if the engraftment rate is #26/29,
the regimen was considered to have no benefit of
engraftment potential. Differences between categoric
variables were analyzed by chi-square test, Fisher’s
exact test, or linear by linear association test.Differences
between means of continuous variables were calculated
with Student’s t-test. Cumulative incidences (CI) were
estimated for acute GVHD (aGVHD), chronic
GVHD (cGVHD), cytomegalovirus (CMV) infection,
Epstein-Barr virus (EBV) infection, and treatment-
relatedmortality (TRM)to takecompeting risks into ac-
count. Kaplan-Meier method and log-rank univariate
comparisons were used to estimate the probability of
survival. Cox propotional hazard regression model was
used for the multivariate analysis of prognostic factors
affecting survival. SPSS version 17.0was used for all sta-
tistical analyses and statistical significance was accepted
for P\.05.RESULTS
Engraftment Data
The median infused cell dose of nucleated cells
and CD34-positive cells were 6.8 108/kg (1.3-39.9
108/kg) and 5.2  106/kg (1.2-27.0  106/kg), respec-
tively. The median number of days required for ANCBM) and Mobilized Peripheral Blood (PB)
BM (N 5 15) PB (N 5 13) P-Value
.000
3.1 (1.3-9.6) 17.0 (6.8-26.5)
2.5 (1.2-6.3) 8.6 (4.7-23.8)
.244
9 10
5 3
1
.014
9 2
4 5
2 6
.000
16 (14-32) 12 (10-15)
.433
11 7
.699‡
6 4
1 1
1
.065‡
3/12 1/13
3/12 1/13
D, graft-versus-host disease; MTX, methotrexate; PTLD, posttransplan-
. on days 7, 9, and 11).
Table 3. Regimen-Related Toxicities
Body System Grade I Grade II Grade III Grade IV
Bladder
Hematuria 3 3 6 1
Cardiac
Pericardiac effusion 1 1
CNS
Depressed level of
consciousness
1 1
Seizure 3
Coagulation
Thrombotic microangiopathy 2
Constitutional
Weight gain 1
GI
Diarrhea 8 3 1
Vomiting 6 5 6 1
Stomatitis 4 5 3
Hepatic
Bilirubin 11 2 1
SGOT/SGPT 10 1 4
Infection
Febrile neutropenia 7 2
Infection (documented
microbiologically) with
neutropenia
3* 1†
Catheter-related infection 1 1
Pulmonary
Dyspnea 1 2
Pneumonitis/pulmonary
infiltrates
2 1 2
Renal
Proteinuria 2 2
Creatinine 2 3 2 1
Skin
Rash/desquamation 4 3 1
CNS indicates central nervous system; GI, gastrointestinal.
Data assessed 42 days after transplantation according to the NCI Com-
mon Toxicity Criteria (CTC 2.0).
*Respiratory syncytial virus, Pseudomonas aeruginosa, Stenotrophomonas
maltophilia.
†Streptococcus pneumoniae.
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(10-35 days) and 16 days (11-40 days), respectively.
Spontaneous platelet recovery to more than 20 
109/L required a median of 22 days (22-182 days)
except for 1 patient who died before recovery.Myelog-
enous engraftment in themobilized PBSC transplanta-
tion (PBSCT) was significantly faster than that in the
BMT (P \.001) (Table 2). All patients become
transfusion independent, and they achieved donor-
type hematologic recovery (donor-type chimerism of
.90%). Until the day of analysis (November 2009),
there was no report of secondary graft failure.
GVHD and Prophylaxis
Among the 3 kinds of GVHD prophylaxis, FK was
administered more frequently to the PBSCT than the
BMT (P 5 .014) (Table 2). Grade II–IV aGVHD
occurred in 13 patients and the CI was 46.4%, with
the majority being grade II. Grade III-IV aGVHD oc-
curred in only 3 patients and the CI was 10.9%. The
CI of grade II-IV aGVHD in patients receiving BM
(53.3%) was not significantly different from that of
patients who received PB (38.5%) (P 5 .699).
cGVHD occurred in 8 patients and the CI was
34.8%. Extensive cGVHD occurred in 4 patients and
CI was 17.4%. The CI of cGVHD in patients received
BM (54.6%) was not significantly different from that of
patients who received PB (16.7%) (P 5 .065).
Toxicity
No patients experienced veno-occlusive disease,
but grade III-IV regimen-related toxicity until 42
days after transplantation occurred in 18 (64%) pa-
tients. Grade IV pulmonary toxicity with pneumoni-
tis/pulmonary infiltrates and dyspnea occurred in 2
patients, including 1 with proven respiratory syncytial
virus infection. Grade IV SGOT/SGPT elevation
occurred in 4 patients but was not associated with
aGVHD. Grade IV diarrhea, vomiting, bilirubin,
and skin rash occurred in a patient with grade IV
aGVHD confirmed by biopsy. Toxicities are pre-
sented in Table 3.
Infection and TRM
CMV infection developed in 19 patients with
69.1% of the CI, and CMV disease occurred in 2 pa-
tients (pneumonia and enteritis) with 7.3% of the CI.
Five patients developed posttransplantation lympho-
proliferative disorder (PTLD) with 22.5% of the CI
and 2 of them developed after the treatment of
GVHD. The CI of PTLD in patients with previous
history of IST before SCT (16.4%) was not different
from that of others (29.1%) (P 5 .696). Patients
received treatment including rituximab for PTLD.
Nine patients died of TRM and the CI was 32.1%.
The causes of TRMwere thromboticmicroangiopathy(N 5 2), pneumonia (N 5 1), myocardiac infarction
(N 5 1), PTLD (N 5 3), and cGVHD-associated
complications (N 5 2). Myocardiac infraction oc-
curred in a 14-year-old female at 75 days after trans-
plantation diagnosed by the echocardiogram and
cardiac enzymes, but the cause was not proven. The
cause of death associated with PTLD was progressive
disease in 2 patients and sepsis after chemotherapy for
lymphoma in 1 patient. One patient who received 8
doses of rituximab for steroid refractory cGVHD
(NCT00472225) died of fungal sepsis and another
died of pulmonary complication of cGVHD.Survival Data
The estimated survival rate (SR) of 28 patients was
67.9% (Figure 1). The SR of 13 patients who received
PB (76.9%) was not different from that of the others
who received BM (60.0%) (P 5 .351), and the SRs ac-
cording to each GVHD prophylaxis regimen (CsA 1
MTX 1 rATG: 72.7%, CsA 1 MTX: 66.7%,
FK 1 MTX: 62.5%) were not significantly different
(P 5 .946). The SR of 19 patients with 8/8 HLA
Figure 1. The survival data. (A) The estimated survival rate (SR) of enrolled 28 patients was 67.9%. (B) The SR of patients who received more than
15 units of RBC before transplantation (45.5%) was lower than that of the other patients (82.4%), significantly (P 5 .048).
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(68.4%) was not different from that of mismatched
patients (66.7%) (P 5 .731). The SR of 14 patients
with the history of IST (57.1%) was not significantly
different from that of patients who received first-line
unrelated SCT (78.6%) (P 5 .162). The interval from
diagnosis (\1 year: 76.9%, $1 year: 60.0%) did not
affect survival (P 5 .366). Yet, the SR of 11 patients
who received more than 15 units of RBC before trans-
plantation (45.5%) was lower than that of the other
patients (82.4%), significantly (P 5 .048) (Figure 1).
Among the factors affecting the outcomes, including
the stem cell source, history of previous IST, and the
interval from diagnosis to SCT, only the amount of
transfusion before transplantation ($15 units) was
a significant prognostic factor for survival on multivar-
iate analysis (Table 4). The amount of transfusion
before transplantation ($15 units) was not associated
with the interval from diagnosis to SCT (P 5 .934)DISCUSSION
The data onmatched unrelated transplant in SAA is
still insufficient with the previous studies showing
a 28% to 94% of overall survival (OS), and the optimal
conditioning regimen has not yet been established
[13,14]. Intensification of the conditioning regimens
by the addition of irradiation has improved theTable 4. Multivariate Analysis of Factors Affecting Survival
Outcome measure
(number of patients) Relative Risk (95% CI) P-Value
RBC transfusion $15 units 5.767 (1.212-27.434) .028
History of IST 3.167 (0.702-14.289) .134
HLA mismatch $1/8 2.060 (0.472-8.933) .337
Diagnosis to transplant $1 year 0.706 (0.123-4.129) .706
Stem cell source: BM versus PB 0.355 (0.059-2.134) .258
BM indicates bone marrow; IST, immune suppressive therapy; PB, mobi-
lized peripheral blood; CI, confidence interval; RBC, red blood cell.outcome with enhanced engraftment rate [4,5,15-17],
and a recent systemic review presented the use of
radiation in the majority of patients [18]. Yet radiation
has a deteriorative effect on growth, development, en-
docrine function, fertility, and so on [19,20], and the
incidence of secondary malignancy is higher for the
irradiation-containing conditioning regimen [21,22].
To avoid these problems, the nonradiation fludarabine-
based conditioning regimen has been studied with
promising results [6,10,23-25]. Among the studies
that have used Flu, Cy, and ATG for unrelated stem
cell transplantation (SCT) in SAA, our previous
preliminary report and an EBMT-SAAWP study
used the same kind of ATG preperation, namely,
thymoglobulin [6,10].
The rationale for the selection of thymoglobulin
was presented in our previous report [10]. Briefly, thy-
moglobulin had been found to be more effective and
potent than the other anti-T cell antibody prepara-
tions for preventing GVHD and graft failure, and it
was used as part of a conditioning regimen for aplastic
anemia with promising results [6,7,15,26,27].
In our previous preliminary study and our present
phase II multicenter study, a total of 33 patients
achieved donor type engraftment, which implies that
engraftment can be successfully achieved without radi-
ation [10]. The study of EBMT-SAAWP reported
18% of graft failure. Although these studies used the
same combination of Flu, Cy, and thymoglobulin, we
started our study before the report of the EBMT-
SAAWP using a higher dose of Cy (200 mg/kg versus
1,200 mg/m2) and a lower dose of thymoglobulin (7.5
mg/kg versus 15 mg/kg) than that of the EBMT-SAA
study, although the dose of Flu was same (120 mg/m2).
The characteristics of the present study were the
relatively younger age of the enrolled patients, a high
proportion (46%) of PBSCT, we allowed each institu-
tion’s GVHD prophylaxis regimen, we allowed
first-line HSCT, we included only matched (6/6 in se-
rologic typing for HLA A/B and low-resolution
Biol Blood Marrow Transplant 16:1582-1588, 2010 1587Unrelated Transplant in SAAmolecular typing of HLA DR) unrelated transplant,
and we excluded mismatched related transplantation.
The recipient age has been proven to be a potential
prognostic factor in many studies, and the younger pa-
tients showed better engraftment and outcomes [18].
Although the majority of patients in our study were
young as this was a multicenter study of the Korean
Society of Pediatric Hematology-Oncology, 4 patients
were over the age of 18 years and 3 of them alive now
including a 30 years old female. This result implied
that similar conditioning regimen could be applicable
to adults.
Worse outcomes andmore cGVHDwere reported
when performing transplantation with PB than BM in
HLA-matched sibling donor transplants for young pa-
tients with SAA [28], and the use of BM as a stem cell
source rather than PB has been strongly recommended
for SAA as the GVL effect is not necessary [14]. In our
study, the results of transplantwithPBandBMwerenot
different and FK was administered more frequently to
the PBSCT patients than to the BMT patients. FK
has been known to bemore potent thanCsA in prevent-
ingGVHD[29], and it has been shown superior survival
in the setting of unrelated BMT [30]. Recently, many
donors have preferred PB rather than BM, owing to
the convenience after the official allowance of unrelated
PBSCT by the government in Korea. Although BM is
strongly recommended for transplantation to treat
SAA, if only PB donor is available, it should not be
avoided, and the use of intense GVHD prophylaxis
agents such as FK might improve the outcome of
PBSCT for SAA, and this should be clarified in future.
First-line unrelated transplants were performed
without previous IST in half of our enrolled patients.
Although IST has remained first-line therapy for
patients without a matched related donor, IST has
achieved limited improvement in survival and with
the development of transplantation technique, promis-
ing results of unrelated transplantation (first-line or
salvage after failure of IST) that were comparable to
those of transplantation from a matched related donor
were reported in SAA [31,32]. Early intervention was
recommended for better outcomes, whatever the
first-line therapy, owing to the improvement of both
first-line-related and unrelated transplantation [33].
We decided not to exclude first-line HSCT for pa-
tients with appropriate unrelated donors as IST could
increase the number of the required transfusions,
which might induce allo-immunization and effects
that are deteriorative to the success of unrelated
HSCT. As HSCT with a matched related donor has
become a standard therapy for SAA after the develop-
ment of an excellent regimen, matched unrelated
HSCT could become one of standard options for those
patients without a matched related donor if optimal
conditioning regimens and GVHD prophylaxis are
developed.Among the factors affecting the outcomes, the
amount of RBC transfusion was significant in this
study, but not the interval from diagnosis to transplan-
tation. Multitransfused AA patients are known to have
increased rates of graft rejection after HSCT because
of alloimmunization, which adversely impacts survival
rates [34,35]. But the amount of transfusion did not
affect engraftment in our study. Iron overload by
transfusion is known to increase complications,
infections, and TRM after HSCT [36,37]. Although
we did not assess the exact amount of iron overload
before transplantation, it might have affected the
outcome of our study. As reported previously,
introduction of intensive iron chelating therapy
before SCT could improve the outcome [37].
The engraftment was successful in our study and
veno-occlusive disease did not occur. But high-grade
regimen-related toxicities were observed in more
than half of patients and incidence of the CMV infec-
tion and PTLD were also high, which implies that our
conditioning regimen might have been somewhat too
intensive. After we achieved statistically significant
engraftment potential of our conditioning regimen,
we closed this study before the planned enrollment
of 29 patients.
Now we are performing a newly designed multi-
center study (NCT00882323) to decrease the TRM
by reducing the dose of Cy (120 mg/kg) with the
hope of achieving better outcomes of unrelated trans-
plantation for SAA.ACKNOWLEDGMENTS
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